GCP
APVO icon

GSA Capital Partners’s Aptevo Therapeutics APVO Stock Holding History

GSA Capital Partners’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96K Buy
21,539
+1,901
+10% +$9.15K 0.01% 1627
2026
Q1 		$84K Buy
+19,638
New +$134K 0.01% 1572
2021
Q4 		– Hold
0
– -$211K – 1398
2021
Q3 		– Hold
0
– – – 1210
2020
Q4 		– Hold
0
– -$308K – 1185
2020
Q3 		– Hold
0
– – – 712

Other funds holding APVO

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

GSA Capital Partners's APVO Position: Q2 2026 in Review

GSA Capital Partners increased its Aptevo Therapeutics (APVO) stake by 9.7% in Q2 2026, buying an estimated $9.15K and bringing the position to 21,539 shares worth $96K. The position accounts for 0.01% of the portfolio, ranked #1627.

GSA Capital Partners first reported a position in APVO in Q1 2026 and has held it in 2 quarters since. 2 funds tracked by Wall St. Rank hold APVO as of Q2 2026.

  • GSA Capital Partners held 21,539 shares of Aptevo Therapeutics worth $96K as of Q2 2026.
  • GSA Capital Partners bought 1,901 Aptevo Therapeutics shares in Q2 2026, an estimated $9.15K.
  • Aptevo Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1627 holding.
  • GSA Capital Partners first reported a position in Aptevo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 2 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.